BioSig Technologies (BSGM) Stock: Why The Price Increased 3.96% Today

By Amit Chowdhry ● Apr 19, 2022
  • The stock price of BioSig Technologies Inc (NASDAQ: BSGM) increased by 3.96% today. This is why.

The stock price of BioSig Technologies Inc (NASDAQ: BSGM) – a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform – increased by 3.96% today. Investors are responding positively to BioSig Technologies announcing that the company would be exhibiting at Heart Rhythm 2022, due to take place on April 29 – May 1, 2022, at the Moscone Center in San Francisco, CA.

Clinical observations collected by BioSig’s PURE EP System will be featured in a poster presentation, titled Elimination Of Harmonic Ringing In Intracardiac Signals Using Dynamic Algorithmic Notch Filtering, and co-authored by Amin Al-Ahmad, M.D.; G Joseph Gallinghouse M.D.; Thomas Ladas, M.D.; Domenico Della Rocca M.D.; Matthew Dare; and Andrea Natale, M.D., of St David’s St. David’s Medical Center in Austin Texas. The presentation session will take place at Pod #12 on Sunday, May 1st, 2022.

During the event, BioSig is going to be exhibiting at booth 1071. And the company’s executive leadership, clinical and commercial teams will host a series of technology demonstrations, including features of its newly released PURE EP NOVA-5 Software. Enhanced with NOVA-5 Software, the PURE EP System delivers a new standard in signal processing, offering greater customization and smarter workflows.

Plus BioSig will provide an outlook on current developments and the future of its signal processing technology during a presentation series titled, Signal Processing Pipeline Discovery on Friday, April 29th and Saturday, April 30th. And physicians attending the conference may reserve sessions by appointment.

The PURE EP System is an FDA 510(k) cleared non-invasive class II device that aims to enhance physician workflow and increase procedural efficiency and efficacy in cardiac electrophysiology. And to date, 75 physicians have completed more than 2,200 patient cases with the PURE EP System.

The clinical data acquired by the PURE EP System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. And the study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.